Safety and Synergy of Capmatinib Plus Stereotactic Radiotherapy in MET Exon 14-Mutated Non-Small Cell Lung Cancer: A Case Report
Othmane Bensalah, Meryem Naciri, Mohamed Ali Boudraa, Fatimaezzahra Aouzah, Fadila Kouhen · 2025
Read Safety and Synergy of Capmatinib Plus Stereotactic Radiotherapy in MET Exon 14-Mutated Non-Small Cell Lung Cancer: A Case Report by Othmane Bensalah, Meryem Naciri, Mohamed Ali Boudraa, Fatimaezzahra Aouzah, Fadila Kouhen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12822516.txt.
Description
Othmane Bensalah and co-authors report, in a 2025 case paper, a lung cancer paired care that held for two years. The man, 73, had a right top lung lump, chest node spread, bone spread, and a small brain spot. The tumor bore a MET exon 14 skip, a rare mark. Care mixed capmatinib, a drug that blocks MET, with pin-point rays to the bone spots and then the lung lump. The drug was held five days each side of each ray run. A bone guard drug rode as well.
No grave harm came. Scans showed the lumps shrink and hold; the brain spot cleared in full. At 24 months he lives with no spread seen. The pair was safe and strong in this case.
Catalog record
| CREATOR | Othmane Bensalah, Meryem Naciri, Mohamed Ali Boudraa, Fatimaezzahra Aouzah, Fadila Kouhen |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |